SEARCH

SEARCH BY CITATION

References

  • 1
    Bengtsson E, Neame PJ, Heinegård D, Sommarin Y. The primary structure of a basic leucine-rich repeat protein, PRELP, found in connective tissues. J Biol Chem. 1995; 270(43):2563944.
  • 2
    Heinegård D, Aspberg A, Franzén A, Lorenzo P. Glycosylated matrix proteins. In: Royce PM, Steinmann B, editors Connective tissue and its heritable disorders: molecular, genetic, and medical aspects. New York: John Wiley & Sons; 2002. p.27191.
  • 3
    Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A, Ahrman E, Capece D, Iansante V, Zazzeroni F, Alesse E, Heinegård D, Teti A. The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. J Cell Biol. 2009; 187(5):66983.
  • 4
    Bengtsson E, Aspberg A, Heinegård D, Sommarin Y, Spillmann D. The amino-terminal part of PRELP binds to heparin and heparan sulfate. J Biol Chem. 2000; 275(52):40695702.
  • 5
    Del Fattore A, Teti A, Rucci N. Bone cells and the mechanism of bone remodelling. Front Biosci (Elite Ed). 2012; 4:230221.
  • 6
    Weinstein RS, Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011; 365(1):6270.
  • 7
    McLeod KM, Johnson CS. A systematic review of osteoporosis health beliefs in adult men and women. J Osteoporos. 2011; 2011:197454.
  • 8
    Burnham JM, Leonard MB. Bone disease in pediatric rheumatologic disorders. Curr Rheumatol Rep. 2004; 6(1):708.
  • 9
    Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20 Pt 2):6243 s–9s.
  • 10
    Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010; 36(8):61520.
  • 11
    Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011; 11(6):41125.
  • 12
    Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, Redini F, Heymann D. Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des. 2010; 16(27):29817.
  • 13
    Dustan CR, Felsenberg D, Siebel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Natl Clin Pract Oncol. 2007; 4(1):4255.
  • 14
    Coleman R. The use of bisphosphonates in cancer treatment. Ann NY Acad Sci. 2011; 1218:314.
  • 15
    Sekyi-Otu A, Bell R, Andrulis I, Pollak M. Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. J Natl Cancer Inst. 1994; 86(8):62832.
  • 16
    Duan Z, Zhang L, Liu J, Xiang X, Lin H. Early protective effect of total hypoxic preconditioning on rats against systemic injury from hemorrhagic shock and resuscitation. J Surg Res. 2012; 178(2):84250.
  • 17
    Coleman RE. Risk and benefits of bisphosphonates. Br J Cancer. 2008; 98(11):173640.
  • 18
    Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011; 364(18):172837.
  • 19
    Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003; 349(5):45763.
  • 20
    Bachrach LK. Consensus and controversy regarding osteoporosis in the pediatric population. Endocr Pract. 2007; 13(5):51320.
  • 21
    Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007; 25(28):44317.
  • 22
    Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther. 2007;(9Suppl 1):S7.
  • 23
    Burkiewicz JS, Scarpace SL, Bruce SP. Denosumab in osteoporosis and oncology. Ann Pharmacother. 2009; 43(9):144555.
  • 24
    Adler RA. Cancer treatment-induced bone loss. Curr Opin Endocrinol Diabetes Obes. 2007; 14(6):4425.
  • 25
    Bengtsson E, Mörgelin M, Sasaki T, Timpl R, Heinegård D, Aspberg A. The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor. J Biol Chem. 2002; 277(17):150618.
  • 26
    Happonen KE, Furst CM, Saxne T, Heinegård D, Blom AM. PRELP protein inhibits the formation of the complement membrane attack complex. J Biol Chem. 2012; 287(11):8092100.